Back to top
more

Masimo Corporation (MASI)

(Delayed Data from NSDQ)

$246.11 USD

246.11
318,566

-5.09 (-2.03%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 253)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Masimo (MASI) Earnings and Revenues Beat Estimates in Q4

Masimo (MASI) continues to gain from its key Product segment, which witnessed solid growth in Q4.

Urmimala Biswas headshot

4 Medical Products Stocks Set to Beat This Earnings Season

Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.

Is a Surprise Coming for Masimo Corporation (MASI) This Earnings Season?

Masimo Corporation (MASI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Masimo (MASI) Announces Full Market RollOut of SafetyNet-OPEN

Masimo (MASI) SafetyNet-OPEN aids organizations in detecting those who are most vulnerable to COVID-19.

Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry

Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.

Why the Earnings Surprise Streak Could Continue for Masimo (MASI)

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Masimo's (MASI) iSirona to Boost Hospital Automation Platform

Masimo's (MASI) iSirona helps in efficient workflow in hospitals by providing continuous connectivity, thereby helping clinicians to improve patient outcomes.

Masimo (MASI) Reports Encouraging 2020 Preliminary Results

Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.

Debanjana Dey headshot

Digital Health M&As Gain Precedence in the New Normal

The booming digital health space has been witnessing significant M&A activities amid the pandemic.

Masimo's (MASI) Telehealth Solution Helps in COVID-19 Crisis

Masimo (MASI) is lending support to Renown Health through Masimo SafetyNet in order to manage the COVID-19 surge.

Masimo (MASI) Releases Favorable Findings on Pulse Oximetry

Researchers on probe discover that the use of Masimo's (MASI) SpHb was related to the lower rate of postoperative transfusion, minimal duration of ICU stay and other better outcomes.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q3

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.

Masimo (MASI) Q3 Earnings and Revenues Top Estimates

Masimo (MASI) delivered earnings and revenue surprises of 42.86% and 1.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?

The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results

Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?

Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

Solid performance by the net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the third quarter.

Varian (VAR) to Report Q4 Earnings: What's in the Offing?

Varian's (VAR) solid Oncology platform is expected to have driven fiscal fourth-quarter performance.

Cerner (CERN) to Report Q3 Earnings: What's in the Offing?

Cerner's (CERN) third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.

PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?

PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.

DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?

DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

Masimo (MASI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aphria (APHA) to Report Q1 Earnings: What's in the Offing?

Aphria's (APHA) fiscal first-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.

Why Masimo (MASI) is Poised to Beat Earnings Estimates Again

Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?

Intuitive Surgical's (ISRG) third-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment.

Sriparna Ghosal headshot

3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic

Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.